Sutro Biopharma (STRO) Prepaid Assets (2017 - 2026)
Sutro Biopharma (STRO) posted Prepaid Assets of $5.5 million for Q4 2025, down 47.9% sequentially from $10.6 million in Q3 2025, and down 68.98% YoY from $17.8 million in Q4 2024.
Sutro Biopharma (STRO) Prepaid Assets (2017 - 2026) Analysis & Trends
Sutro Biopharma has reported Prepaid Assets for 9 years, with the latest figure at $5.5 million in Q4 2025.
- Quarterly Prepaid Assets fell 68.98% year-over-year to $5.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.5 million (down 68.98% YoY) and the FY2025 annual result came in at $5.5 million, down 68.98% from the prior year.
- Prepaid Assets fell to $5.5 million in Q4 2025 per STRO's latest filing, from $10.6 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $24.9 million in Q1 2025 and troughed at $5.5 million in Q4 2025.
- A 5-year average of $11.5 million and a median of $10.2 million in 2023 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2021 and 2025: Prepaid Assets soared 232.69% in 2021, then tumbled 68.98% in 2025.
- Over 5 years, Prepaid Assets stood at $8.1 million in 2021, then soared by 43.63% to $11.7 million in 2022, then slipped by 15.61% to $9.8 million in 2023, then surged by 80.77% to $17.8 million in 2024, then tumbled by 68.98% to $5.5 million in 2025.
- According to Business Quant data, Prepaid Assets over the past three periods registered $5.5 million, $10.6 million, and $18.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.50 Mn |
| Dec 31, 2025 | 5.52 Mn |
| Sep 30, 2025 | 10.60 Mn |
| Jun 30, 2025 | 18.50 Mn |
| Mar 31, 2025 | 24.88 Mn |
| Dec 31, 2024 | 17.80 Mn |
| Sep 30, 2024 | 10.87 Mn |
| Jun 30, 2024 | 10.53 Mn |
| Mar 31, 2024 | 10.06 Mn |
| Dec 31, 2023 | 9.85 Mn |
| Sep 30, 2023 | 9.48 Mn |
| Jun 30, 2023 | 10.34 Mn |
| Mar 31, 2023 | 17.70 Mn |
| Dec 31, 2022 | 11.67 Mn |
| Sep 30, 2022 | 11.06 Mn |
| Jun 30, 2022 | 8.20 Mn |
| Mar 31, 2022 | 7.91 Mn |
| Dec 31, 2021 | 8.12 Mn |
| Sep 30, 2021 | 8.70 Mn |
| Jun 30, 2021 | 9.75 Mn |